)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited (RGC) investor relations material
Regencell Bioscience Holdings Limited Q4 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2026 earnings summary7 Oct, 2026
Executive summary
Early-stage TCM developer focused on ADHD and ASD; no approved products or product revenue, with standardized formula still in development.
FY2026 loss widened as operating costs rose; May 2026 offering strengthened liquidity, and management judged cash sufficient for at least 12 months.
Financial highlights
Product revenue remained $0 in FY2026 and FY2025; operating expenses were $11.72M vs. $3.77M, up 211% YoY.
Net loss was $11.70M vs. $3.58M in FY2025; loss per share was $2.37 vs. $0.72, on a cents-per-share basis.
G&A expense rose to $10.42M from $2.81M, driven by $3.13M higher professional fees, $3.02M higher share-based compensation amortization and $1.47M higher payroll.
R&D expense increased to $1.30M from $0.95M, mainly due to higher payroll; selling and marketing fell to $6.49K from $8.01K.
Outlook and guidance
No product revenue expected until standardized TCM products are commercialized in Hong Kong; launch depends on further development, registration and manufacturer licensing.
Next trial design and research partnerships are being explored; planned AI, blockchain and tokenization initiatives remain conceptual, with execution and regulatory feasibility uncertain.
Cash at June 30, 2026 was assessed as sufficient for operating needs and obligations for at least the next 12 months; further financing may be pursued for reserves or expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Regencell Bioscience Holdings Limited
Next Regencell Bioscience Holdings Limited earnings date
Q1 202716 Dec, 2026
Regencell Bioscience Holdings Limited
Next Regencell Bioscience Holdings Limited earnings date
Q1 202716 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Regencell Bioscience Holdings Limited is a biotechnology company focused on developing traditional Chinese medicine-based treatments for neurocognitive disorders and degenerative conditions. The company’s research aims to address conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), utilizing natural and holistic treatment approaches. Regencell's therapies are grounded in traditional medical practices, combined with modern scientific methods, to offer alternative treatment options for patients with these neurological conditions. The company is headquartered in Hong Kong, and its shares are listed on the Nasdaq.